Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Sym004 in Recurrent Glioblastoma
NCT02540161Phase 2Completed
- Sponsor
- Istari Oncology
- Start
- Feb 2016
- Primary completion
- Jul 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of futuximab + modotuximab in glioblastoma (GBM) (4 arms), sponsored by Istari Oncology. Primary endpoint: Six-month Progression-free Survival at 6 months. Started Feb 2016; status: completed.
02
Drugs
futuximab + modotuximab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02540161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540161.